Happy holidays from all of us at BVD! We’re grateful to all of our collaborators, team members, and the investigators and patients who participate in clinical studies of our investigational medicines. Thank you for your partnership in advancing hope for life.
Biomed Valley Discoveries
Biotechnology Research
Kansas City, MO 985 followers
Biotech, Purposefully Reimagined
About us
Biomed Valley Discoveries, Inc. (BVD) is a clinical-stage biotechnology company on a quest to make a meaningful difference for patients and their families. HOPE FOR LIFE BVD is guided exclusively by our founders’ intent of bringing hope for life to patients. Our founders, Jim and Virginia Stowers, envisioned a biotech company that could approach the pursuit of groundbreaking medicines differently from the traditional biotech model. Jim Stowers founded the asset management firm, American Century Investments (ACI), which today manages over $200 billion in assets. Over 40% of annual profits from ACI are directed to the Stowers Group of Companies, including the Stowers Institute for Medical Research and BVD, providing a stable and sustainable source of funding to further scientific and clinical innovation. BIOTECH, PURPOSEFULLY REIMAGINED Our secure funding and our commitment to our founders’ intent have enabled us to build a purposefully reimagined biotech company, with distinct approaches to candidate sourcing, research and development, compassionate use/expanded access, collaborations, partnering/out-licensing, and overall corporate infrastructure. CURRENT PROGRAMS Our 3 novel oncology assets hold the potential to address significant unmet needs: -Ulixertinib, a highly selective, first-in-class ERK 1/2 inhibitor -TEM8 therapeutic antibodies, including TEM8-directed antibody drug conjugates (ADCs) -Clostridium novyi-NT, a cancer-fighting bacteria PARTNERING & OUT-LICENSING We are structured to take assets through early development to proof-of-concept. While we have the flexibility to advance niche/orphan disease programs through registration, our model is primarily centered around partnering and out-licensing our programs beyond this point. A prospective partner or out-licensee could be any organization with a vested interest in advancing a de-risked asset for a serious unmet medical need, from large or mid-size biopharma companies to venture capital firms.
- Website
-
http://www.biomed-valley.com
External link for Biomed Valley Discoveries
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Kansas City, MO
- Type
- Privately Held
- Founded
- 2007
Locations
-
Primary
Kansas City, MO, US
Employees at Biomed Valley Discoveries
-
Marcel Meth
SharePoint Consultant/Developer/Analyst (Intranets, Document Management, Collaboration & AIs)
-
David Tung, Ph.D., BDCP, CMCCP, PDCP
-
Anna Groover
Senior Scientist, Translational Sciences at BioMed Valley Discoveries
-
Caroline Emery
Director at BioMed Valley Discoveries, Inc.
Updates
-
We’re excited to share that our collaborators at MD Anderson Cancer Center will be presenting a poster at the Society for Neuro-Oncology (SNO) Annual Meeting highlighting data showing that our investigational ERK 1/2 inhibitor, ulixertinib, penetrates the blood/brain barrier and has demonstrated early signals of efficacy in adults with MAPK-activated lower grade gliomas. Stop by the poster to learn more! #SNO2024 #BrainCancer #BrainTumors #CancerResearch #ClinicalOncology #NeuroOncology #NeuroOnc #MAPK #LowGradeGliomas #NF1 #Neurofibromatosis
-
At last week’s 6th Annual RAS-Targeted Drug Development Summit in Boston, our president Brent Kreider gave a plenary presentation on ulixertinib, our highly selective ERK 1/2 inhibitor. Dr. Kreider described the encouraging clinical activity and tolerability profile we've observed to date with ulixertinib, including the drug's potential role in treating cancers that become resistant via MAPK pathway reactivation. BVD is looking to advance possible combinations with RAS, RAF, and MEK inhibitors as an important strategy to help patients with MAPK pathway-driven cancers. Reach out to us at BD@biomed-valley.com to discuss. Learn more about ulixertinib: https://lnkd.in/enwuqs9J #ERK #RAS #RAF #BRAF #MAPK #CancerResearch #FightCancer #TargetedTherapies #DrugDevelopment
-
We’re looking forward to next week’s 6th Annual RAS-Targeted Drug Development Summit in Boston! Brent Kreider, BVD’s president, will give a plenary presentation on our lead clinical program, ulixertinib, a highly selective ERK 1/2 inhibitor. The presentation will include an overview of the encouraging clinical activity and tolerability profile observed to date and ulixertinib’s potential role in overcoming resistance via the reactivation of the MAPK pathway. Learn more about the conference: https://lnkd.in/d-29jaH Learn more about ulixertinib: https://lnkd.in/enwuqs9J Reach out if you’d like to connect with us there: BD@biomed-valley.com #ERK #RAS #MAPK #CancerResearch #FightCancer #TargetedTherapies #DrugDevelopment
-
We’re back from the ESMO - European Society for Medical Oncology 2024 Congress, which offered a wonderful few days engaging with others who share our dedication to fighting cancer. Rooted in our founders’ intent to build a biotech company solely dedicated to delivering #HopeForLife to patients, the common thread across our programs is novel science and biology with the potential to address significant unmet needs in cancer and other serious conditions. For example, with our lead program ulixertinib, we’re focused on unlocking the potential of ERK inhibition to deliver a new, durable treatment option for patients with MAPK pathway-driven cancers. ERK activation is the final and necessary step in the MAPK signaling cascade. Direct inhibition of ERK could substitute for or be an important complement to other MAPK pathway inhibitors, particularly to overcome resistance mechanisms. Ulixertinib has demonstrated ERK family selectivity with limited off-target inhibition, giving it a potent and highly selective on-target profile that distinguishes it from other ERK inhibitors. Given the encouraging clinical activity and tolerability profile observed to date, we believe ulixertinib holds the potential to be an important treatment option for thousands of patients with MAPK pathway-driven cancers who currently have limited treatment options. Learn more about ulixertinib: https://lnkd.in/enwuqs9J #ESMO24 #ERKinhibition #MAPKpathway #CancerResearch #OncologyCongress
-
We’ve arrived in Barcelona and are excited to kick off the first day of the ESMO - European Society for Medical Oncology 2024 Congress! Enabled by our unique “reimagined biotech” model, we are pursuing bold and potentially transformative translational and clinical efforts in areas of significant unmet need. For example, we’re harnessing TEM8/ANTXR1 – an over-expressed protein on cancer-associated cells – as a powerful lamp post to guide anti-cancer payloads into the tumor microenvironment. There have been approximately 160 publications on TEM8/ANTXR1 over the past 20 years, including research showcasing promising findings for TEM8/ANTXR1 as a relevant cancer biomarker. Nevertheless, to date, TEM8/ANTXR1 has largely remained unexplored therapeutically. We believe TEM8/ANTXR1-directed antibody-drug conjugates have the potential to serve as a cornerstone across multiple therapeutic modalities in several solid tumor cancers. Learn more about our TEM8/ANTXR1 program: https://lnkd.in/ewp6MZ2U #ESMO24 #AntibodyDrugConjugates #ADC #CancerResearch #OncologyCongress
-
We’re excited to participate in the upcoming 6th Annual RAS-Targeted Drug Development Summit in Boston! BVD President Brent Kreider will give a plenary presentation on ulixertinib, our highly selective, investigational ERK 1/2 inhibitor. As the terminal node in the MAPK pathway, direct inhibition of ERK could be an important complement to inhibitors targeting the upstream MAPK pathway targets such as RAS, particularly to overcome resistance mechanisms. Learn more about the conference: https://lnkd.in/d-29jaH Learn more about ulixertinib: https://lnkd.in/enwuqs9J Reach out if you’d like to connect with us there: BD@biomed-valley.com #ERK #RAS #MAPK #CancerResearch #FightCancer #TargetedTherapies #DrugDevelopment
-
#ICYMI – Over the summer, we announced that the first patient was dosed in a Phase 2 study of ulixertinib, our highly selective, first-in-class ERK 1/2 inhibitor, in individuals with histiocytosis who have progressed on or cannot tolerate other therapies. Histiocytosis can cause tumors throughout the body, fractures and bone lesions, mental deterioration, lung disease, hormonal abnormalities, and many other systemic symptoms. The MAPK signaling pathway – which comprises a sequential cascade of four key signaling nodes – RAS, RAF, MEK and ERK – is implicated in many cases of histiocytosis. We believe ERK inhibition has the potential to overcome the limitations of existing treatments in this pathway and look forward to further exploration through this investigator-initiated trial. Read more: https://lnkd.in/eyn_zjB4 #Histiocytosis #CancerResearch #Oncology #CompassionateUse #MAPK #ErdheimChesterDisease #ErdheimChester #LangerhansCell Histiocytosis Association Erdheim-Chester Disease Global Alliance
-
We’re looking forward to attending ESMO - European Society for Medical Oncology 2024 Congress and engaging with a global community of experts who share our commitment to advancing care for people with cancer. Reach out if you’d like to connect with us in Barcelona to learn more about ulixertinib, our highly selective, investigational ERK 1/2 inhibitor; or our TEM8/ANTXR1-directed antibody-drug conjugates. Learn more about ulixertinib: https://lnkd.in/enwuqs9J Learn more about our TEM8/ANTXR1 program: https://lnkd.in/ewp6MZ2U #ESMO24 #ERKinhibition #MAPKpathway #AntibodyDrugConjugates #ADC #CancerResearch #OncologyCongress
-
September is Childhood Cancer Awareness Month, and our hearts go out to all the children and families facing a cancer diagnosis. At BVD, we are committed to bringing hope for life to those with challenging diseases. In the near future, we plan to extend this mission to address childhood cancer with the initiation of a clinical trial in pediatric low-grade glioma, a type of brain tumor with few treatment options. We have established the recommended Phase 2 dose of ulixertinib – our highly selective, first-in-class ERK 1/2 inhibitor – for pediatric patients, and we are working toward the initiation of our planned clinical study of ulixertinib in pediatric low-grade glioma. For more information and childhood cancer resources, please visit National Cancer Institute (NCI)’s website: https://lnkd.in/dj3Ntzs #ChildhoodCancer #ChildhoodCancerAwareness #ChildhoodCancerAwarenessMonth #CCAM2024 #PediatricOncology #LowGradeGlioma #BrainCancer #HopeForLife